Novavax, Inc. (NVAX)Healthcare | Biotechnology | Gaithersburg, United States | NasdaqGS
8.84 USD
+0.20
(2.315%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 8.88 +0.04 (0.452%) ⇧ (April 17, 2026, 7:57 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 10:29 p.m. EDT
Novavax presents a high-risk 'reckless bet' scenario. While recent 2-week momentum is technically neutral-to-positive (reversing prior declines from ~7.70 to ~8.84), the underlying fundamentals—negative earnings, negative forward P/E, and a short ratio of 11.12—signal a trap. Heavy put buying at the psychological 7.50-8.00 support suggests prolonged consolidation; upside is strictly limited until significant buying pressure destroys this protective put positioning. It is a speculative currency play, not an investment. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.104058 |
| AutoARIMA | 0.104059 |
| MSTL | 0.115011 |
| AutoTheta | 0.144472 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 62% |
| H-stat | 1.84 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.354 |
| Excess Kurtosis | -0.91 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 6.935 |
| Market Cap | 1,440,353,792 |
| Trailing P/E | 3.43 |
| Forward P/E | -8.72 |
| Beta | 2.65 |
| Profit Margins | 39.19% |
| Website | https://www.novavax.com |
As of April 18, 2026, 10:29 p.m. EDT: Options data reveals significant hedging activity with deep ITM put volume (strikes 7.0, 7.5, 8.0) accumulating heavily in front of April/May expirations, particularly where volume exceeds open interest. This suggests downside protection buying or 'long-put' positioning as a floor. Conversely, out-of-the-money calls show net open interest buildup at 10.0 and 11.0 strikes for near-term expirations, but the overall market mood is defensive. IV is elevated to 1.56 on 5/22 puts, indicating a high-uncertainty environment for near-term volatility.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.47088182 |
| Address1 | 700 Quince Orchard Road |
| All Time High | 331.68 |
| All Time Low | 3.53 |
| Ask | 8.91 |
| Ask Size | 30 |
| Audit Risk | 9 |
| Average Analyst Rating | 2.3 - Buy |
| Average Daily Volume10 Day | 2,816,320 |
| Average Daily Volume3 Month | 4,807,393 |
| Average Volume | 4,807,393 |
| Average Volume10Days | 2,816,320 |
| Beta | 2.648 |
| Bid | 8.6 |
| Bid Size | 2 |
| Board Risk | 4 |
| Book Value | -0.786 |
| City | Gaithersburg |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 5 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 8.84 |
| Current Ratio | 2.127 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 8.97 |
| Day Low | 8.75 |
| Display Name | Novavax |
| Dividend Date | 1,557,446,400 |
| Earnings Call Timestamp End | 1,772,112,600 |
| Earnings Call Timestamp Start | 1,772,112,600 |
| Earnings Timestamp | 1,772,112,600 |
| Earnings Timestamp End | 1,778,157,000 |
| Earnings Timestamp Start | 1,778,157,000 |
| Ebitda | 590,852,992 |
| Ebitda Margins | 0.52591 |
| Enterprise To Ebitda | 1.664 |
| Enterprise To Revenue | 0.875 |
| Enterprise Value | 983,317,760 |
| Eps Current Year | -0.10191 |
| Eps Forward | -1.01391 |
| Eps Trailing Twelve Months | 2.58 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 9.1722 |
| Fifty Day Average Change | -0.33220005 |
| Fifty Day Average Change Percent | -0.03621814 |
| Fifty Two Week Change Percent | 47.08818 |
| Fifty Two Week High | 11.97 |
| Fifty Two Week High Change | -3.13 |
| Fifty Two Week High Change Percent | -0.26148707 |
| Fifty Two Week Low | 5.8 |
| Fifty Two Week Low Change | 3.04 |
| Fifty Two Week Low Change Percent | 0.5241379 |
| Fifty Two Week Range | 5.8 - 11.97 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 818,173,800,000 |
| Float Shares | 140,252,003 |
| Forward Eps | -1.01391 |
| Forward P E | -8.718722 |
| Free Cashflow | -331,942,880 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 749 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.63519 |
| Gross Profits | 713,619,008 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04987 |
| Held Percent Institutions | 0.69671 |
| Implied Shares Outstanding | 162,935,945 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://www.novavax.com/go.cfm?do=Stock.GetQuote |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,557,446,400 |
| Last Split Factor | 1:20 |
| Long Business Summary | Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. |
| Long Name | Novavax, Inc. |
| Market | us_market |
| Market Cap | 1,440,353,792 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_350381 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | 440,302,016 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,440,353,753 |
| Number Of Analyst Opinions | 9 |
| Open | 8.88 |
| Operating Cashflow | -244,635,008 |
| Operating Margins | 0.14229 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.32 |
| Phone | 240 268 2000 |
| Post Market Change | 0.03999996 |
| Post Market Change Percent | 0.45248824 |
| Post Market Price | 8.88 |
| Post Market Time | 1,776,470,221 |
| Previous Close | 8.64 |
| Price Eps Current Year | -86.7432 |
| Price Hint | 2 |
| Price To Book | -11.2468195 |
| Price To Sales Trailing12 Months | 1.2820477 |
| Profit Margins | 0.39191002 |
| Quick Ratio | 1.83 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.33333 |
| Region | US |
| Regular Market Change | 0.2 |
| Regular Market Change Percent | 2.31481 |
| Regular Market Day High | 8.97 |
| Regular Market Day Low | 8.75 |
| Regular Market Day Range | 8.75 - 8.97 |
| Regular Market Open | 8.88 |
| Regular Market Previous Close | 8.64 |
| Regular Market Price | 8.84 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 2,347,436 |
| Return On Assets | 0.25724 |
| Revenue Growth | 0.666 |
| Revenue Per Share | 6.935 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 5 |
| Shares Outstanding | 162,935,945 |
| Shares Percent Shares Out | 0.2761 |
| Shares Short | 44,990,492 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 50,923,803 |
| Short Name | Novavax, Inc. |
| Short Percent Of Float | 0.2771 |
| Short Ratio | 11.12 |
| Source Interval | 15 |
| State | MD |
| Symbol | NVAX |
| Target High Price | 25.0 |
| Target Low Price | 7.0 |
| Target Mean Price | 14.0 |
| Target Median Price | 16.0 |
| Total Cash | 735,084,032 |
| Total Cash Per Share | 4.511 |
| Total Debt | 278,048,000 |
| Total Revenue | 1,123,479,040 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 2.58 |
| Trailing P E | 3.4263568 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 8.1317 |
| Two Hundred Day Average Change | 0.7083006 |
| Two Hundred Day Average Change Percent | 0.087103635 |
| Type Disp | Equity |
| Volume | 2,347,436 |
| Website | https://www.novavax.com |
| Zip | 20,878 |